ZAGG Introduces Award-Winning ZAGGaudio Line
SALT LAKE CITY--(BUSINESS WIRE)--ZAGG Inc. (OTCBB: ZAGG - News), leading producer of mobile electronics accessories, unveils its new Z.buds earphones. Marking ZAGG’s entry into the headphones market, the Z.buds has been named 2009 CES Innovations Design and Engineering Showcase Honoree. CES Innovations Honorees are chosen by a panel of judges and recognize inventive consumer electronics that stand out in a crowded market as leaders in their respective industries. In a sleek design, the Z.buds integrates passive noise cancellation, allowing music and user conversations to be heard more clearly. The Z.buds’ high-end audio provides a full sound that is comparable to earbuds of twice the price. Its innovative and durable nylon cord is designed with several wearability options,...

Wellstar/TMI Imaging System Being Utilized in Breast Cancer Study at Duke University Medical Center
HOLLAND, OH--(MARKET WIRE)--Nov 21, 2008 -- Wellstar International, Inc. (OTC BB:WLSI - News), a provider of specialized diagnostic software and equipment, announced today that the Department of Radiation Oncology at Duke University Medical Center (DUMC) has disclosed its utilization of the Trillenium Medical Imaging system ("TMI") to validate the system's potential to measure the clinical response rates to novel therapies indicated in recurrent breast cancer patients. According to Oana Craciunescu, the medical physicist for this study at DUMC, "The TMI Medical Imaging System has been implemented since the spring of 2007; the study's principal objective is to examine the system's ability to help clinicians decide if patients are responding to treatment....

Most Active OTCBB Stocks

Burzynski Research Institute, Inc. (BRI) Presents Promising Phase II Data on Malignant Glioma
HOUSTON & LAS VEGAS--(BUSINESS WIRE)-- (BZYR)Today at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology, BRI announced encouraging results from the ongoing Phase II clinical trials of two of its investigational drugs, Atengenal (A10) and Astugenal (AS2-1), defined as antineoplastons therapy (ANP). The meeting is currently taking place in Loews Lake, Las Vegas, Nevada. Background – Phase II Study in Anaplastic Astrocytoma - In this Phase II clinical trial, ANP is administered daily on an outpatient basis, via an ambulatory infusion pump, to adult patients with newly-diagnosed anaplastic astrocytoma (AA), a common type of malignant glioma. The prognosis for patients with AA is usually poor with five-year’s survival in less than 30% of patients, even after surgery, chemotherapy and radiation therapy....